(CercleFinance.com) – Novartis announced on Wednesday that it has taken the decision, with Medicines for Malaria Venture (MMV), to advance their drug project against malaria caused by the parasite plasmodium falciparum.
The biopharmaceutical group indicates that this decision was taken after this new antimalarial drug candidate reached its primary endpoint in a phase 2 study involving 524 people.
The phase 3 study, due to start early next year, will compare the effectiveness of the combination of ganaplacid and lumefantrine against the current standard treatment for the disease.
The trial will be conducted at several clinical sites in Burkina Faso, Mali, Gabon, Niger and other countries in sub-Saharan Africa.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
